Differential alterations in gene expression profiles contribute to time-dependent effects of nandrolone to prevent denervation atrophy by Qin, Weiping et al.
RESEARCH ARTICLE Open Access
Differential alterations in gene expression profiles
contribute to time-dependent effects of
nandrolone to prevent denervation atrophy
Weiping Qin
1,2, Jiangping Pan
1, William A Bauman
1,2,3, Christopher P Cardozo
1,2,3*
Abstract
Background: Anabolic steroids, such as nandrolone, slow muscle atrophy, but the mechanisms responsible for this
effect are largely unknown. Their effects on muscle size and gene expression depend upon time, and the cause of
muscle atrophy. Administration of nandrolone for 7 days beginning either concomitantly with sciatic nerve
transection (7 days) or 29 days later (35 days) attenuated denervation atrophy at 35 but not 7 days. We reasoned
that this model could be used to identify genes that are regulated by nandrolone and slow denervation atrophy,
as well as genes that might explain the time-dependence of nandrolone effects on such atrophy. Affymetrix
microarrays were used to profile gene expression changes due to nandrolone at 7 and 35 days and to identify
major gene expression changes in denervated muscle between 7 and 35 days.
Results: Nandrolone selectively altered expression of 124 genes at 7 days and 122 genes at 35 days, with only 20
genes being regulated at both time points. Marked differences in biological function of genes regulated by
nandrolone at 7 and 35 days were observed. At 35, but not 7 days, nandrolone reduced mRNA and protein levels
for FOXO1, the mTOR inhibitor REDD2, and the calcineurin inhibitor RCAN2 and increased those for ApoD. At 35
days, correlations between mRNA levels and the size of denervated muscle were negative for RCAN2, and positive
for ApoD. Nandrolone also regulated genes for Wnt signaling molecules. Comparison of gene expression at 7 and
35 days after denervation revealed marked alterations in the expression of 9 transcriptional coregulators, including
Ankrd1 and 2, and many transcription factors and kinases.
Conclusions: Genes regulated in denervated muscle after 7 days administration of nandrolone are almost entirely
different at 7 versus 35 days. Alterations in levels of FOXO1, and of genes involved in signaling through calcineurin,
mTOR and Wnt may be linked to the favorable action of nandrolone on denervated muscle. Marked changes in
the expression of genes regulating transcription and intracellular signaling may contribute to the time-dependent
effects of nandrolone on gene expression.
Background
Androgens have been shown to reverse muscle loss due
to age [1,2], and to preserve muscle in persons with
HIV infection [3,4] and burns [5,6]. In animal models,
androgens also prevent or reduce atrophy due to disuse
from spinal cord injury [7], immobilization [6], or
unweighting [8]. The molecular basis for these beneficial
effects remains poorly understood.
One major factor that contributes to muscle atrophy is
accelerated catabolism of muscle proteins, which is lar-
gely attributable to the ubiquitin-proteasome pathway
[9] and which has been linked to the muscle ubiquitin
E3 ligases muscle atrophy F-box (MAFbx) and muscle
Ring-finger 1 (MuRF1) [10-12]. Upregulation of MAFbx
and MuRF1 has been attributed to activation of FOXO1
[13,14]. Degradation by MAFbx of the muscle differen-
tiation factor MyoD [15] or the translation initiation fac-
tor eIF3F [16] have also been linked to muscle atrophy.
In cardiac myocytes, MAFbx also reduces calcium-
dependent signaling through calcineurin and has been
shown to reduce myocyte size [17].
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tors of protein synthesis acting both up- and downstream
of mTOR, a protein kinase that integrates signals regulat-
ing protein synthesis and cell size and has also been impli-
cated in muscle hypertrophy [18,19]. Reductions in mTOR
activity caused by dexamethasone or ethanol have been
shown to be due to upregulation of REDD1 (also known
as DDIT4 or RTP801) [20,21]. mTOR is also inhibited by
REDD2 (also called DDIT4L or RTP801L), a protein clo-
sely related to REDD1 [22,23]. Expression of REDD1 is
upregulated by FOXO1 [24], as is that of 4EBP1 [25],
which inhibits translation by reducing the initiation of
CAP-dependent translation by eIF4E [26].
We have recently found that administration for 7 days
of the anabolic steroid nandrolone reduced denervation
atrophy when begun 29 days after nerve transection (35
days) associated with reduced levels of mRNA for
MAFbx and MuRF1, but without changes in expression
of IGF-1, its receptor, or IGF-1 binding proteins 2, 3, 4
or 5 [27]. However, when begun at the time of denerva-
tion, administration of nandrolone for the same 7 day
period (7 days) did not prevent atrophy or reduce
expression of MAFbx or MuRF1 [27]. The molecular
mechanisms by which nandrolone slows atrophy at 35
days are unclear. While MAFbx and MuRF1 accelerate
denervation atrophy in mice [10] and degrade several
proteins that determine muscle mass [15-17], their levels
do not necessarily correlate to the response to interven-
tions that spare muscle [28]. Thus, there are likely to be
additional actions of nandrolone that contribute to its
protective effects on denervated muscle at 35 days. In
addition, the molecular determinants that prevent the
anabolic actions of nandrolone at 7 days are unknown.
We reasoned that comparison of genes regulated by nan-
drolone at 7 and 35 days would permit identification of
those genes regulated only at 35 days, and which are thus
likely to be associated with protection against atrophy. Addi-
tionally, we predicted that the changes in gene expression in
denervated muscle between 7 and 35 days formed the basis
for the increased responsiveness to nandrolone at 35 days;
because many actions of nandrolone involve its binding to
the androgen receptor (AR), a transcription factor that is
activated when drug or hormone are bound, we predicted
that there were changes over this period in the expression
of genes encoding factors that either promoted or prevented
transcriptional activity of the AR at target genes. Here, we
have tested these possibilities using oligonucleotide microar-
rays with verification of the expression of selected genes by
real time PCR (qPCR) and Western blotting.
Results
Filtering of microarray data
Probesets representing 124 known genes (Pool A)w e r e
altered by nandrolone in denervated gastrocnemius at 7
days after nerve transection (Figure 1B and Additional
file 1). At 35 days, nandrolone changed the expression
of 276 genes (Pool D, data not shown) in denervated
gastrocnemius muscle.
Before comparing Pools A and D,w ee x a m i n e dt h e
possible confounding effects of changes in gene expres-
sion over time due to the effects of denervation on skele-
tal muscle. A comparison of gene expression in
denervated gastrocnemius muscle from animals adminis-
tered vehicle revealed 318 unique genes that were altered
at day 35 as compared to day 7 (Pool E, Additional file
2). Among these, 154 were also present in Pool D and
were altered in the same direction by time (35 versus 7
days) and nandrolone. These genes were removed from
Pool D, resulting in a new Pool B with 122 genes (Figure
1B and Additional file 3). Surprisingly, only 20 genes in
Pool A were also present in Pool B (Pool C, Figure. 1B).
Thus, the majority of genes regulated by nandrolone at
35 days were not altered by this agent at 7 days.
GO categories of genes altered by nandrolone
Genes regulated by nandrolone were grouped according
to their designations in the gene ontology database (GO
categories) to delineate common groupings and biologi-
cal networks activated or suppressed in denervated mus-
cle by nandrolone at 7 or 35 days. The biological
functions of genes regulated by nandrolone at both time
points are depicted in Figure 2. This analysis revealed
marked differences in the biological functions of genes
regulated by nandrolone at both of the time points. At 7
days, the most significant groupings were for cell cycle,
cell death, cellular development and cancer, whereas at
35 days, the most significant p values were for lipid
metabolism, molecular transport and small molecule
biochemistry, categories that were not significantly
enriched at 7 days (Figure 2). Cell-cell signaling, and
cardiovascular system development and function were
also enriched only at 35 days, whereas categories for
gene expression, and skeletal and muscular system
development, were enriched only at 7 days. Cell cycle,
connective tissue development and function, skeletal
and muscle disorders and cancer were enriched at both
7 and 35 days. Thus, functional groupings of genes
regulated by nandrolone differed at 7 and 35 days.
Genes altered by nandrolone at 7 or 35 days
Genes regulated by nandrolone at 7 days were further
filtered based upon known, or potential, roles in muscle
atrophy or hypertrophy, or in transcriptional regulation
by the AR; the genes selected are shown in Table 1. For
the purposes of comparison, the effects of nandrolone
on these genes at 35 days are also shown. A similar
selection process was used to identify genes of potential
interest that were regulated by nandrolone at 35 days
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Page 2 of 17(Table 2), which, again are shown together with corre-
sponding effects of nandrolone at 7 days. A heat map
depicting normalized expression values for each indivi-
dual microarray for selected genes that were significantly
a l t e r e db yn a n d r o l o n ea t3 5d a y si ss h o w ni nF i g u r e3 .
Comparison of expression changes in Table 2 with cor-
responding changes for each microarray (Figure 3)
revealed good agreement. Overall, the direction and
relative magnitude of change was similar among the
microarrays for each of the genes examined.
Effects of nandrolone on gene expression by biological
function
Translation At 35 days, nandrolone reduced expression
of two inhibitors of translation, REDD2, and Eef2 kinase
(Table 2). At 7 days, nandrolone did not significantly
alter expression of either gene.
A. 124 genes changed at 7 days in denervated gastrocnemius (Nandrolone vs Vehicle).
B. 122 genes changed at 35 days in denervated gastrocnemius (Nandrolone vs Vehicle).
C. 20 genes changed by nandrolone at both 7 days and 35 days.
C B A
Denervation+Nandrolone
Denervation Nandrolone
(-) protection
(+) protection
0                            7 days     
0                                                                                                                             28 days                         35 days 
A.
B.
C
Figure 1 Summary of the experimental design and of the overlap of genes regulated by nandrolone at 7 and 35 days. A. Scheme of
the experimental design. B. Venn diagram depicting the overlap of genes regulated by nandrolone at 7 and 35 days.
Figure 2 Biological functions for nandrolone-regulated genes at 7 and 35 days. Common groupings and biological functions of genes
regulated in denervated muscle at 7 or 35 days were determined using Ingenuity Pathways analysis. Numbers in parentheses indicate the p
value for enrichment of the corresponding GO biological function.
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Page 3 of 17Development and Muscle Development Nandrolone
altered expression of genes in development at 35 days
by 2- to 5-fold. It upregulated clusterin (Clu) and devel-
opmentally regulated GTP-binding protein 1 (Drg1),
and downregulated Dicer1 and sortilin 1 (SORT1)
(Table 2). At 7 days, nandrolone increased SORT1
expression, but did not significantly alter expression of
Clu, Drg1, or Dicer1 (Table 2). At 35 days, nandrolone
induced expression of two genes linked to muscle devel-
opment, myotrophin (Mtpn), a growth factor, and AE
binding protein 1 (AEBP1), a transcription factor (Table
2). At 7 days, myotrophin expression was unaffected by
nandrolone while AEBP1 expression was increased, but
t h em a g n i t u d eo ft h ec h a n g ew a st h r e eq u a r t e r so ft h a t
stimulated by nandrolone at 35 days (Table 2). At 7
days, nandrolone reduced expression of one gene linked
to muscle development, Cmya1_predicted (Additional
file 1).
Calcium/calmodulin-mediated signaling Several genes
encoding molecules involved in calcium/calmodulin-
mediated signaling were differentially altered at 35 days
as compared to 7 days. Regulator of calcineurin 2
(RCAN2/DSCR1L1) was significantly downregulated by
nandrolone at 35 days but was upregulated at 7 days
(Table 2). Thrombospondin 1 (THBS1) was upregulated
by nandrolone at 35 days but down-regulated at 7 days
(Table 1). Calcineurin B, type1 (Ppp3r1) was up
regulated by nandrolone at 35 days but unchanged at 7
days (Table 2).
Growth factors and response to wounding Nandrolone
altered the expression of several growth factors. At 35
days, nandrolone markedly upregulated apolipoprotein-
D (Apo D, Table 2) and galanin (GAL, Table 1). At 35
days, nandrolone also upregulated osteoglycin, chemo-
kine (C-C motif) ligand 7 and chemokine (C-C motif)
receptor 1 (Table 2) and the Wnt inhibitors secreted
frizzled-related peptides 2 and 4 (Additional file 3).
Expression of these genes was not affected by nandro-
lone at 7 days, with the exception of galanin (Table 1).
At 7 days, nandrolone upregulated osteomodulin, adipo-
nectin-C1q and collagen domain containing, and
Sema3b (Additional file 1). At 7 days, nandrolone down-
regulated sclerostin domain containing 1 (Additional file
1), a BMP-1 antagonist [29].
Protein kinases and their regulators Genes encoding
or regulating protein kinases were also differentially
regulated by nandrolone at both 7 and 35 days. At 35
days, nandrolone upregulated the following: protein
kinase inhibitor alpha (Pkia); the a1 catalytic subunit of
AMP-activated protein kinase (Prkaa1); and Sprouty
protein with EVH-1 domain 1 related sequence
(SPRED1) (Table 2). At 35 days, nandrolone downregu-
lated the gamma 3 non-catalytic subunit of AMP-acti-
vated protein kinase (Prkag3), and calcium/calmodulin-
Table 1 Selected GO category and genes that are altered at 7 days denervation, and comparison with expression at
35 days.
GO category Gene Name Gene Symbol 7 days (Nan vs
Veh)
35 days (Nan
vs Veh)
Calcium/calmodulin-mediated
signaling
Thrombospondin 1 THBS1 -2.27 2.55
Muscle contraction Galanin GAL -1.43 10.82
Tropomyosin 3, gamma TPM3 -2.00 -1.12
Proteolysis A disintegrin-like and metallopeptidse with
thrombospondin type 1 motif, 1
ADAMTS1 -1.69 2.33
Serpin peptidase inhibitor, class E, member 1 SERPINE1 -2.86 3.09
Steroid_hormone_receptor_activity Nuclear receptor subfamily 4, group A, member 1 NR4A1 -4.00 1.75
Nuclear receptor subfamily 4, group A, member 2 NR4A2 -1.89 2.12
Nuclear receptor subfamily 4, group A, member 3 NR4A3 -5.88 1.28
Transcription Activating transcription factor 3 ATF3 -5.56 2.36
B-cell leukemia/lymphoma 6 BCL6_PREDICTED -1.72 -1.06
Basic helix-loop-helix domain containing, class B3 BHLHB3 1.67 -1.05
B-cell translocation gene 2, anti-proliferative BTG2 -2.63 1.58
Transcription factor 4 TCF4 -1.39 1.18
Transducin-like enhancer of split 1, homolog of
Drosophila E(spl)
TLE1_PREDICTED -1.75 -1.08
Splicing factor, arginine/serine-rich 10 (transformer 2
homolog, Drosophila)
SFRS10 1.55 -1.09
Ubiquitin -Proteasome Pathway Ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog,
yeast)
UBE2E2 -1.32 -1.08
Ubiquitin specific protease 12 USP12_PREDICTED -1.23 1.35
Abbreviation: Nandrolone, Nan; Vehicle, Veh.
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Page 4 of 17Table 2 Selected GO category and genes that are altered at 35 days, and comparison with changes at 7 days.
GO category Gene Name Gene
Symbol
35 days 7 days
(Nan vs
Veh)
(Nan vs
Veh)
Calcium/calmodulin-mediated signaling Regulator of Calcineurin 2 (Down syndrome critical region
gene 1-like 1)
RCAN2 -1.69 1.26
Calcium/calmodulin-dependent protein kinase II, alpha Camk2a -3.23 -1.30
Calcineurin B, type1 Ppp3r1 2.11 1.12
Cell cycle G0/G1 switch gene 2 G0s2 2.07 -1.45
Transducer of ERBB2, 2 Tob2 -1.43 1.03
Cell proliferation Protein phosphatase 1, catalytic subunit, beta isoform PPP1CB -1.92 1.02
EGL nine homolog 3 EGLN3 -1.64 1.12
Development Clusterin Clu 2.52 1.05
Developmentally regulated GTP binding protein 1 Drg1 3.97 1.24
Dicer1 Dicer1 -2.00 -1.14
Sortilin 1 SORT1 -1.82 1.50
G-protein coupled receptor protein signaling
pathway
Regulator of G-protein signaling 2 RGS2 1.96 1.08
Guanine nucleotide binding protein, alpha 12 GNA12 1.94 1.07
GNAS complex locus GNAS -2.38 1.24
Growth factor Apolipoprotein D Apo D 14.73 3.00
Osteoglycin OGN 2.60 1.27
Muscle development Myotrophin Mtpn 1.92 1.02
AE binding protein 1 AEBP1 3.44 2.60
Muscle contraction Myosin binding protein H Mybph -1.82 1.15
Nervous system development Myelin basic protein MBP 12.06 2.85
Protein kinase Protein kinase, AMP-activated, gamma 3 non-catalytic
subunit
Prkag3 -1.64 1.05
Protein kinase inhibitor, alpha Pkia 2.47 -1.08
Protein kinase, AMP-activated, a1 catalytic unit Prkaa1 1.93 -1.14
Sprouty protein with EVH-1 domain 1, related sequence SPRED1 2.93 1.58
Response to wounding Chemokine (C-C motif) ligand 7 CCL7 1.70 1.05
Chemokine (C-C motif) receptor 1 CCR1 1.55 1.23
Transcription Early growth response 1 Egr1 2.28 -2.33
Early growth response 2 Erg2 2.54 -3.85
Early growth response 3 Egr3 2.29 -4.76
Forkhead box protein O1A FOXO1 -2.22 1.22
Transforming, acidic coiled-coil containing protein 2 TACC2 -2.38 1.41
Nuclear protein 1 Nupr1 2.17 1.37
Heat shock transcription factor 4 HSF4 -1.72 1.10
carboxy-terminal domain, RNA polymerase II, polypeptide A Ctdsp1 -1.54 1.06
Grainyhead-like 1 Grhl1 -2.70 1.22
Human immunodeficiency virus type I enhancer binding
protein 1
HIV EP1 1.72 1.16
TSC22-related-inducible leucine zipper protein 2 TSC22 -1.19 2.30
Translation Eukaryotic elongation factor-2 kinase Eef2k -2.44 1.24
DNA-damage-inducible transcript 4-like REDD2/
DDIT4L
-1.72 -1.32
Ubiquitin -Proteasome Pathway Sequestosome 1 SQSTM1 -1.92 1.37
UBIQUITIN-CONJUGATING ENZYME E2H Ube2h 1.97 1.12
Wnt signaling pathway Casein kinase 1, alpha 1 Csnk1a1 -2.44 -1.37
Abbreviations: Nandrolone, Nan; Vehicle, Veh.
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Page 5 of 17dependent protein kinase II, alpha (Camk2a) (Table 2).
At 7 days, nandrolone upregulated SPRED1, although to
a lesser extent than at 35 days, but did not alter expres-
sion of Pkia, Prkag3, or Camk2a (Table 2). At 7 days,
nandrolone downregulated tribbles homolog 1, a modu-
lator of MAPK pathways (Additional file 1).
Transcription/RNA processing At 35 days, nandrolone
upregulated selected transcription factors by 1.5- to 2.8-
fold, including early response genes (Egr1, Egr2, and
Egr3), the human immunodeficiency virus type I enhan-
cer binding protein 1 (HIV EP1), and Nupr1, a tumor
suppressor that regulates transcription and has been
Clu    
Drg1
Dicer1
RGS2
GNA12
GNAS
ApoD
OGN
MTPN
AEBP1
Mybph
MBP
Prkag3
Pkiα
SPRED1
CCL7
CCR1
Development
G-protein protein coupled receptor 
protein  signaling pathway 
Growth factor 
Muscle development 
Nervous system development 
Protein kinase 
Response to wounding 
RCAN2   
Camk2a
Ppp3r1
G0s2
PPP1CB
EGLN3
Egr3
Egr1
FOXO1
Nupr1
HDF4
Grhl1
HIV EP1
Eef2k
REDD2
SQSTM1
Ube2h
Csnk1a1
Calcium/calmodulin-mediated signaling 
Cell cycle 
Cell proliferation 
Wnt  signaling pathway 
Transcription factors 
Translation 
Ubiquitin-Proteasome Pathway 
-2.0            0             2.2
-1.3            0             6.5
Figure 3 Heat maps for selected genes regulated at 35 days. Heat maps were generated by TM4 MultiExperiment Viewer Version 4.3.02
http://www.tm4.org using microarray expression data for selected genes from Pool B. Red represents up-regulation, while green represents
downregulation. The color scale bar indicates Log2 ratio of intensities (Nan ÷ Vehicle)]. Genes are grouped by the biological functions are
indicated.
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Page 6 of 17associated with cardiac muscle hypertrophy [30] (Table
2). Nandrolone also upregulated ATF3 at 35 days (Table
1). At 35 days, nandrolone repressed forkhead box pro-
tein O1A, more commonly referred to as FOXO1, the
designation used hereafter. Also repressed by nandro-
lone at 35 days were transforming, acidic coiled-coil
containing protein 2 (TACC2), and heat shock tran-
scription factor 4 (HSF4) (Table 2). Genes for three
transcriptional coregulators were repressed by nandro-
lone at 35 days: grainyhead like (Grhl1), AT hook, and
carboxyterminal domain RNA polymerase II small phos-
phatase (Ctdsp1) (Table 2 and Additional file 3).
A striking aspect of the genes altered at 7 days was
that the 6 genes most greatly downregulated by nandro-
lone were transcription factors (range -4.8 fold for Egr3
to -2.33 for Egr1) (Table 2). These included the early
response factors Egr1-3 (Table 2), as well as Ier2 and
Ier5 (Additional file 1), some of which were upregulated
by nandrolone at 35 days (Egr1-3) (Table 2). At 7 days,
nandrolone repressed three orphan nuclear receptors
(NR4A1, NR4A2 and NR4A3) (Table 1) and several
transcriptional coregulators: Ankrd1, one of a family of
molecules that transmits signals from the contractile
apparatus to the nucleus [31] (Additional file 1), and
TLE1_PREDICTED, a transcriptional corepressor (Table
1). Also repressed were BTG2, an antiproliferative factor
which regulates transcription in a p53-dependent man-
ner, and BCL6_PREDICTED, a transcriptional repressor
involved in morphogenesis (Table 1).
At 35 days, nandrolone altered expression of genes
involved in RNA processing. Notable among these was
Dicer 1, as noted above (Table 2). At 7 days, nandrolone
reduced expression of DEAH (Asp-Glu-Ala-His) box
polypeptide 36, an RNA helicase (Additional file 1).
Other pathways A t3 5 ,b u tn o t7d a y s ,n a n d r o l o n e
upregulated expression of ubiquitin-conjugating enzyme
E2H (Ube2h) and down-regulated sequestosome 1
(SQSTM1) (Table 2). Nandrolone downregulated ring
finger protein (C3H2C3) 6, an SCF type ubiquitin ligase,
at 35 but not 7 days (Additional file 3). Nandrolone also
down-regulated the Wnt-signaling molecule casein
kinase 1, alpha 1 (Csnk1a1) (Table 2) at 35 days.
Validation of cDNA microarray results with qPCR To
confirm selected microarray results, and to examine bio-
logical variability among equivalently treated animals,
we examined mRNA levels in denervated gastrocnemius
muscles using real time PCR. In this analysis, we also
included FOXO3A, which is closely related to FOXO1
and exerts similar effects on the expression of MAFbx
[13]. There was good agreement between the microarray
and qPCR data as far as direction and relative magni-
tude of changes in gene expression. At 35 days, nandro-
lone significantly increased expression of ApoD and Clu
and decreased expression of REDD2, RCAN2, FOXO1,
Dicer 1, CamK2a, Csnk1a1 and HSF4 (Figure 4). At 7
days, effects of nandrolone on gene expression were: in
the opposite direction for FOXO1, FOXO3A and
Camk2a; smaller for REDD2, Clu and, ApoD; and mini-
mal for RCAN2, Csnk1a1 and HSF4 (Figure 4).
Western blotting Effects of nandrolone on levels of
selected proteins in denervated gastrocnemius muscle
were assessed by Western blotting. These effects agreed
well with changes in mRNA levels (Figures 4 and 5).
Nandrolone significantly reduced levels of RCAN2,
FOXO1 and REDD2 at 35 but not 7 days, and signifi-
cantly increased ApoD levels at 35 days but not 7 days
(Figure 5).
Changes over time in gene expression in denervated
muscle
Microarray data
Gene expression in denervated muscle from vehicle-
treated rats was compared at 7 and 35 days. A complete
listing of the genes for which expression was found to
change significantly between 7 and 35 days is shown in
Additional file 2. This list included 318 unique genes
involved in cell growth and proliferation, connective tis-
sue development and function, cell cycle, and cell death.
Genes demonstrating altered expression included
those expressing kinases, phosphatases and transcrip-
tional regulators but not growth factors. When compar-
ing expression levels at 35 versus 7 days for
transcriptional coregulators, CREBBP, RNPC2, PRRX1,
Nrip1 and NMI were upregulated by 2- to 3.98-fold
while Tgif, Lmcd1, Ankrd1 and Ankrd2 were downregu-
lated from -2.75-to -23.81-fold (Table 3). There were 24
other transcriptional regulators for which expression
changed between 7 and 35 days, with alterations in
expression ranging from a 3.28-fold increase to -6.85-
fold decrease (Table 3). The largest increases in expres-
sion were for TSC22D4, BHLHB3, and DBP, while the
greatest decreases in expression were observed for
BTG2, Egr2, and RCAN1 (Table 3).
Seventeen kinases demonstrated significant changes in
expression ranging from a 4.08-fold increase to a -2.84-
fold decrease. Kinases with the most highly increased
expression included ERBB2, NTRK2, and PIK3C2B,
while those with the greatest decrease in expression
included MPP6, TRIB1, and UCK2 (Table 3). Seven
phosphatases demonstrated altered expression, with 6
being decreased by -1.54- to -3.62-fold and one being
increased by 6.96-fold (protein tyrosine phosphatase,
receptor type D, PTPRD) (Table 3).
Verification of selected microarray data by real time PCR
The results of the microarray analysis were confirmed
for selected genes by real time PCR (Figure 6). A com-
parison of findings from microarray and real time PCR
analysis revealed that the direction and magnitude of
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Page 7 of 17change in expression were similar. As compared to 7
days, expression at 35 days was significantly different for
the transcriptional coregulators Ankrd1, Ankrd2, and
C R E B B P ,a sw e l la sf o rt h et r a n s c r i p t i o nf a c t o r sA t f 5
and LIMCD 1.
Correlation between gene expression changes and
nandrolone response
To gain insights into physiological significance of gene
expression changes, we analyzed the relationship between
gastrocnemius muscle size at3 5d a y sa n dm a g n i t u d eo f
gene expression change induced by nandrolone. For this
analysis we chose the two genes for which nandrolone
had the largest effect on mRNA levels as determined by
real time PCR: RCAN2 and ApoD. There was a signifi-
cant negative correlation between RCAN2 mRNA levels
and gastrocnemius muscle weight (Figure 7A). A positive
correlation was observed between ApoD mRNA and
weights of denervated gastrocnemius (Figure 7B).
Discussion
Nandrolone effects on gene expression over time
This study sought insights into the molecular basis for
the observation that administration of nandrolone for 7
days slowed denervation atrophy when begun at day 29
after nerve transection (35 days), but had no effect on
atrophy when initiated at the time the nerve was severed
(7 days). The findings indicated that nandrolone regu-
lated an almost entirely different set of genes at 7 days
compared to 35 days. A marked change in the expres-
sion in denervated muscle of genes involved in the con-
trol of transcription and intracellular signaling was
observed between 7 and 35 days.
Among genes regulated by nandrolone at 35 but not 7
days were molecules that drive muscle atrophy
(FOXO1), inhibit protein synthesis (REDD2), regulate
calcineurin (RCAN2), and determine Wnt signaling
(Csnk1a1). FOXO1 is a transcription factor known to
reduce muscle size [32,33], and to upregulate MAFbx
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Figure 4 Real time PCR quantification of mRNA levels of selected genes altered by nandrolone. A-J. Levels of mRNA for RCAN2, FOXO1,
FOXO3A, REDD2, Dicer 1, HSF1, Clu, Apo D, Csnk1a1 and CaMK2a are shown. Data are presented as means ± SEM. Groups contained 7 to 8
animals. Data were analyzed by one-way ANOVA; p values for the F statistic are shown under each panel. *p < 0.05, **p < 0.01, ***p < 0.001
versus the indicated group.
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Page 8 of 17and MuRF1 and the protein synthesis inhibitor 4EBP1
[13,14,32,34]. Nandrolone-induced reductions in
FOXO1 at 35 but not 7 days agree well with the prior
observation that nandrolone reduced expression of
MAFbx and MuRF1 at 35 but not 7 days [27]. The find-
ings suggest that downregulation of FOXO1 represents
a likely mechanism by which nandrolone slows denerva-
tion atrophy.
To our knowledge, neither RCAN2 nor calcineurin
have been previously suggested to be involved in nandro-
lone action or denervation atrophy. Calcineurin is a cal-
cium-calmodulin-dependent dual-specificity phosphatase
which promotes the slow-twitch endurance muscle fiber
type [35]. At 35 days, nandrolone reduced expression of
RCAN2, and RCAN2 levels were inversely correlated
with the size of denervated gastrocnemius. Nandrolone
also altered the expression of a regulatory subunit of cal-
cineurin, calcineurin B, type 1. Of interest, in studies of
calcineurin function in the pathogenesis of cardiac hyper-
trophy, calcineurin activity has been shown to be reduced
by MAFbx, FOXO1 or FOXO3A, and to be directly
linked to myocardiocyte size [17,36]. The role of calci-
neurin in hypertrophy of normal skeletal muscle hyper-
trophy, or spontaneous recovery from muscle atrophy, is
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Figure 5 Western blotting analysis of protein levels for selected gene products. A-D. Western blotting analysis of the effects of
nandrolone on levels of RCAN2, FOXO1, REDD2, and ApoD proteins in denervated gastrocnemius muscle are shown. Groups contained data for
7 to 8 animals each. Data are presented as means ± SEM and were analyzed by one-way ANOVA; p values for the F statistic are shown under
each panel. *, p < 0.05, **, p < 0.01, ***, p < 0.001 versus the indicated group.
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Page 9 of 17Table 3 Selected GO category and genes that are altered at 35 days denervation, in comparison with 7 days
denervation
GO category Gene Name Gene Symbol Fold-Change
(35 vs 7)
Transcriptional Coregulators creb binding protein CREBBP 3.98
rna-binding region (rnp1, rrm) containing 2 RNPC2 2.85
paired related homeobox 1 PRRX1 2.40
nuclear receptor interacting protein 1 (predicted) Nrip1 2.06
n-myc (and stat) interactor NMI 2.00
homeodomain interacting protein kinase 2 (predicted) Hipk2 -2.54
tg interacting factor Tgif -2.75
lim and cysteine-rich domains 1 (predicted) Lmcd1 -4.27
Ankyrin repeat domain 1 (cardiac muscle) Ankrd1 -4.48
Ankyrin repeat domain 2 (stretch responsive muscle) Ankrd2 -23.81
Transcription Factors and Other
Transcriptional Regulators
TSC22 domain family, member 4 TSC22D4 3.28
basic helix-loop-helix family, member e41 BHLHB3 3.17
D site of albumin promoter (albumin D-box) binding protein DBP 3.07
activating transcription factor 5 ATF5 2.53
MAX gene associated MGA (includes
EG:23269)
2.40
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog,
Drosophila)
MLL 2.38
POZ (BTB) and AT hook containing zinc finger 1 PATZ1 2.34
Kruppel-like factor 5 (intestinal) KLF5 2.25
thyrotrophic embryonic factor TEF 2.25
single-minded homolog 2 (Drosophila) SIM2 2.16
TSC22 domain family, member 3 TSC22D3 2.10
myogenic differentiation 1 MYOD1 2.10
Kruppel-like factor 15 KLF15 2.05
CCAAT/enhancer binding protein (C/EBP), delta CEBPD 2.05
polycomb group ring finger 6 PCGF6 -2.08
SRY (sex determining region Y)-box 4 SOX4 -2.13
v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) MAFF -2.33
zinc finger protein 367 ZNF367 -2.67
Ankyrin repeat and SOCS box-containing 5 ASB5 -2.95
aryl hydrocarbon receptor nuclear translocator-like ARNTL -3.07
LIM and cysteine-rich domains 1 LMCD1 -4.27
regulator of calcineurin 1 RCAN1 -5.05
BTG family, member 2 BTG2 -5.35
early growth response 2 (Krox-20 homolog, Drosophila) Egr2 -6.85
Kinases v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/
glioblastoma derived oncogene homolog (avian)
ERBB2 4.08
neurotrophic tyrosine kinase, receptor, type 2 NTRK2 3.33
phosphoinositide-3-kinase, class 2, beta polypeptide PIK3C2B 2.50
cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial CMPK2 2.43
discoidin domain receptor tyrosine kinase 2 DDR2 2.33
activin A receptor, type IIB ACVR2B 2.28
protein kinase, cAMP-dependent, regulatory, type II, beta PRKAR2B 2.08
EPH receptor B3 EPHB3 1.94
cell division cycle 2-like 6 (CDK8-like) CDC2L6 1.93
protein kinase, AMP-activated, beta 2 non-catalytic subunit PRKAB2 1.89
PTEN induced putative kinase 1 PINK1 1.81
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Page 10 of 17controversial [18,35,37-40]. Its roles in denervated mus-
cle, or androgen action, are unknown. We are now inves-
tigating the relationship between nandrolone action and
calcineurin in atrophied skeletal muscle.
Increased expression of inhibitors of mTOR, such as
REDD1 and REDD2, have been linked to decreases in
cell size and protein synthesis and have been suggested
to promote muscle atrophy [20,21,26,41]. mTOR is a
master regulator of protein synthesis [26,41] and is
necessary for muscle hypertrophy and recovery of mus-
c l es i z ea f t e rm u s c l ea t r o p h y[ 1 8 ] .U p r e g u l a t i o no f
mTOR inhibitors has been described during muscle
Table 3 Selected GO category and genes that are altered at 35 days denervation, in comparison with 7 days denerva-
tion (Continued)
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Figure 6 Real time PCR quantification of mRNA levels of selected transcriptional regulators differentially regulated at 7 versus 35
days. A-E, levels of mRNA for CREBBP, Atf5, Ankrd 1, Ankrd 2 and LIMD 1 are shown. Groups contained data for 7 to 8 animals each. Data are
means ± SEM and were analyzed by one-way ANOVA; p values for the F statistic are shown under each panel. *, p < 0.05, **, p < 0.01, ***, p <
0.001 versus the indicated group.
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Page 11 of 17atrophy caused by glucocorticoids [20] or alcohol inges-
tion [21] and has been implicated in mTOR inhibition
due to glucocorticoids in cultured myoblasts [20]. Of
interest, testosterone prevented upregulation of REDD1
in dexamethasone-treated rats and cultured myoblasts
and normalized mTOR activity in cultured cells exposed
to dexamethasone [42]. Consistent with these findings,
in denervated muscle, nandrolone reduced REDD2
mRNA and protein at 35 but not 7 days, suggesting that
r e d u c t i o ni ne x p r e s s i o no ft h i sp r o t e i n ,a n ds u b s e q u e n t
increases in mTOR activity, may represent one mechan-
ism by which nandrolone slows denervation atrophy.
Other genes upregulated at 35 days by nandrolone
include Wnt signaling molecules (e.g., Csnk1a1, sFRP2
and sFRP4) and ApoD. Wnt signaling appears to be
important to muscle hypertrophy [43,44]. Of interest, in
a cell culture system, the intracellular target of Wnt sig-
naling, b-catenin, can be activated by androgens through
physical interactions between b-catenin and the AR [45].
Upregulation of ApoD, a lipoprotein believed to partici-
pate in uptake or intercellular transport of ligands [46],
correlated well with denervated muscle size at 35 days.
Upregulation of this gene has also been observed in
muscle hypertrophy [47]. The significance of these
changes in ApoD expression is unknown.
Molecular determinants of nandrolone-induced
alterations in gene expression
An additional objective of this study was to examine the
possibility that changes over time in gene expression
could provide insights into the molecular determinants
for the marked time-dependent effects of nandrolone on
gene expression in denervated muscle. These time-
dependent effects were dramatically demonstrated by
the minimal overlap of genes regulated at 7 versus 35
days, despite the fact that over 100 genes were regulated
by this agent at each time point. Equally interesting was
the finding that the list of genes regulated by nandro-
lone at 35 but not 7 days included several shown to be
critical to muscle atrophy, specifically FOXO1 (this
study), and MAFbx and MuRF1 [27].
These time-dependent actions of nandrolone occurred
on a background of changes over time in expression of
over 300 genes in denervated muscle, that included many
genes that function in intracellular signaling and transcrip-
tional regulation, such as kinases, phosphatases, transcrip-
tion factors and transcriptional coregulators. The AR is a
transcription factor, and the classical mechanism by which
drugs such as nandrolone signal through the AR is tran-
scriptional regulation by the AR when bound to chromatin,
or to other transcription factors. Transcriptional activity of
the AR is dependent upon binding of coregulators [48,49],
and interactions with nearby transcription factors. Coregu-
lators modify chromatin structure to repress or transacti-
vate specific genes, and their binding to AR is critical to its
transcriptional control of target genes [48,49].
Interactions between the AR and other transcription
factors form one basis for transcriptional repression (e.g.,
[50] and references cited therein) and can determine
whether a steroid hormone receptor, such as the AR, is
able to transactivate specific genes [51]. Interdependence
of AR actions and levels of specific transcription factors
were illustrated by findings that gene knockdown with
and siRNA against Oct-1 abrogated repression of MAFbx
by testosterone [50]. The concept that levels of a tran-
scriptional regulator can profoundly affect transcriptional
programs was demonstrated by the effects of PGC-1a on
muscle fiber type and mitochondrial biogenesis ([52] and
references therein). Thus, one model that would explain
the time-dependent effect of nandrolone is variation over
time in levels or activity of transcription factors and/or
coregulators with which the AR interacts at target genes.
Figure 7 Correlations for selected genes with gastrocnemius size and RCAN2 mRNA levels. A. Correlation at 35 days between
gastrocnemius muscle weight and mRNA levels for RCAN2. Each data point represents the muscle weight and RCAN2 mRNA level for a single
animal. B. As in a. except that ApoD mRNA levels are shown.
Qin et al. BMC Genomics 2010, 11:596
http://www.biomedcentral.com/1471-2164/11/596
Page 12 of 17Marked changes in the expression of several transcrip-
tional coregulators were observed between days 7 and
35 after denervation, with the most dramatic being the
large reductions in expression levels for Ankrd1 and
Ankrd2. The influence of these coregulators on tran-
scriptional regulation by the AR has not been described.
Among coregulators with less dramatic changes in
expression between 7 and 35 days, several are known to
regulate transcriptional activities of the AR: CREBBP
[53], Tgif [54], Ctdsp1[55] and NRIP1 [56].
Interactions between the AR and other transcription
factors have been reported for GR, Ets1, Oct1, NFkB,
FOXO1 and AP1 [57-63]. Many transcription factors
demonstrated altered expression between 7 and 35 days.
Although interactions of these transcription factors with
the AR have not been reported, it remains possible that
these occur, and that changes in their expression may
be linked to some of the time dependent effects of
nandrolone.
Other mechanisms may also be involved in, or be cri-
tical to, time-dependent effects of nandrolone on gene
expression. These may include changes in phosphoryla-
tion status of transcriptional regulators, or non-genomic
effects of nandrolone mediated through interactions
w i t hk i n a s e s( e . g . ,E R B B 2 ,P I 3 K C 2 B ) ,G - p r o t e i n s ,o r
other intracellular signaling molecules [64]. For example,
it has been demonstrated that transcriptional activity of
PGC-1a is determined by activity of the kinases AMPK
and p38 MAPK [65,66].
Thus, the findings suggest several possible mechan-
isms that may explain the time-dependent effects of
nandrolone on gene expression in denervated muscle.
Future investigations focused on more detailed time
course studies, interactions of proteins encoded by these
regulatory genes with the AR, and their effects on nan-
drolone target genes such as FOXO1 or MAFbx, hold
the promise of identifying the specific molecular interac-
tions by which nandrolone exerts such profoundly dif-
ferent actions over time.
Comparison with other studies of androgen actions in
atrophied muscle
An interesting consideration is that the effects of nan-
drolone to slow atrophy of denervated gastrocnemius
are much greater than its effects to increase the mass of
normal rat muscles, including gastrocnemius, [67] but
that both of these actions of nandrolone are consider-
ably smaller than the dramatic effect of androgens to
increase the size of the rat levator ani muscle [68,69]. It
is possible that similar mechanisms determine androgen
responsiveness of these normal and denervated muscles.
It is also possible that the marked changes in expression
of key regulatory molecules that occurs with time after
denervation play important roles in determining
androgen sensitivity of denervated muscle that are dis-
tinct from those that specify the androgen responses of
normal muscle and the levator ani.
In either case, the time-dependent differences in nan-
drolone effects on denervated muscle appear to be one
manifestation of a more general influence of the physio-
logical state of skeletal muscle on responses to andro-
gens. For example, genes regulated by nandrolone at 7
or 35 days differed from those regulated by androgens
in other genomic studies. In agreement with our find-
ings in denervated muscle at 35 days, in HIV-infected
men, testosterone altered the expression of genes regu-
lating IGF-1 signaling, muscle development, transcrip-
tion, cell cycle and apoptosis, and Wnt signaling, but in
contrast to denervated muscle, not those involved in cal-
cineurin signaling or translation [70]. In dexamethasone-
treated rats, testosterone reversed dexamethasone-
induced changes in expression of FOXO1, but also
reduced expression of REDD1 and 4EBP1 [42], genes
that were not found to be nandrolone responsive in
denervated muscle. In AR-deficient mice, alterations in
gene expression were noted for genes for myoblast dif-
ferentiation and polyamine synthesis, as well as those
for cell cycle progression and Wnt signaling [71]. Loss
of the AR also affected expression of IGF-II and several
other growth factors, but, not genes regulating calci-
neurin signaling or translation [71].
Conclusions
Genes regulated by nandrolone in denervated muscle at
7 days were almost entirely different from those regu-
lated by this agent to 35 days. These time-dependent
nandrolone effects were associated with many changes
in expression in denervated muscle of genes involved in
the control of transcription and intracellular signaling.
Genes regulated by nandrolone at 35 but not 7 days
include factors known to drive muscle atrophy
(FOXO1), inhibit protein synthesis (REDD2), regulate
calcineurin (RCAN2), and determine Wnt signaling.
Marked changes in expression of transcriptional regula-
tors known or suspected to interact with the AR occur
between 7 and 35 days, and their differential regulation
may explain the time-dependence of nandrolone effects
on gene expression in denervated muscle, at least in
part.
Methods
Animals, sciatic nerve transection and drug
administration
The analysis used gastrocnemius muscle from male
Wistar-Hannover rats that had undergone left sciatic
nerve transection followed by the administration of nan-
drolone or vehicle beginning either on the day of sur-
gery or 29 days thereafter. Effects of nandrolone on
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Page 13 of 17gastrocnemius weights and mRNA levels for MAFbx
and MuRF1 have been previously reported [27]. A sum-
mary of the experimental design is presented in Figure
1A. Animals had been sacrificed 7 days after starting
nandrolone or vehicle (e.g, at days 7 or 35). Muscle tis-
sue was flash-frozen at sacrifice and stored at -80 ˚C.
The animal studies were reviewed and approved by the
Institutional Animal Care and Use Committee of the
James J. Peters VA Medical Center.
Microarray analysis
Microarray analysis was performed for total RNA from
12 animals, 3 each from: day 7 vehicle, day 7 nandro-
lone, day 35 vehicle, and day 35 nandrolone; one micro-
array was used for each animal. Total RNA from
gastrocnemius muscles from the denervated hind limb
was used for these studies. Muscle (20 mg) was homo-
genized in guanidinium isothiocyanate buffer on ice
using a Polytron. RNA was extracted using phenol-
chloroform [72], then further enriched using RNAeasy
minicolumns (Qiagen, Valencia, CA). Verification of
RNA integrity and microarray analysis were performed
b yt h eM i c r o a r r a yC o r eF a c i l i t ya tt h eM o u n tS i n a i
School of Medicine. Samples selected for microarray
analysis yielded RNA integrities greater than 8.0 using
an Agilent Bioanalyzer. Microarray analysis employed
Affymetrix rat genome 230 2 arrays and was performed
using the recommended procedures of the manufac-
turer. Microarray data has been deposited in NIH GEO
(Accession number GSE17959).
Data filtering and mining
Differentially expressed genes were identified using BRB
Array Tools version 3.6.2, developed by Dr. Richard
Simon and Amy Peng Lam. Data from the Affymetrix
plate reader was loaded directly into the software. Affy-
metrix Present/Absent calls were not included in the
analysis. Predefined BRB Array Tools software settings
were used for normalization and filtering. Data for each
array were normalized using the median for the entire
array. Expression values were set to 10 when they were
below this value. Expression values were excluded unless
the values for at least 20% of the arrays were 1.5-fold or
more different from the median for that probe set. The
significance of differences in expression among groups
was determined using an F-test, with significance set at
p < 0.05. Because the number of genes modulated by
nandrolone at each time point was not very large, all
probes yielding a significant difference at p < 0.05 were
included in subsequent analysis. For the comparison of
gene expression in denervated muscle at 7 and 35 days,
a much larger number of genes was identified; to limit
the list of candidates somewhat, only those differing at p
< 0.01 were included in subsequent analysis.
Values for fold-change (e.g., nandrolone versus vehicle
at 7 or 35 days) were calculated using geometric means.
Biological functions of differentially expressed genes
were determined using Ingenuity Pathways, NIH
DAVID [73,74] and GeneCards at http://www.genecards.
org[75]. Subsets of genes regulated by nandrolone at 7
or 35 days were selected for additional analysis based
upon known or proposed relationships to muscle atro-
phy and hypertrophy, or transcriptional regulation by
androgens.
Heat maps were generated using the microarray
expression data that had been normalized relative to the
mean for all expression values for the array and were
generated using TM4 MultiExperiment Viewer Version
4.3.02 http://www.tm4.org. Fold change for the expres-
sion value for each gene and microarray was calculated
relative to the arithmetic mean for the vehicle group for
that gene.
Tests for enrichment of biological themes were per-
formed using Ingenuity Pathways Analysis (Ingenuity
systems, http://www.ingenuity.com).
Quantitative real time PCR (qPCR)
Total RNA (1 μg) was used to prepare cDNA libraries
by reverse transcription (High Capacity cDNA Archive
Kit; Applied Biosystems, Fos t e rC i t y ,C A ) .R e a lt i m e
PCR was performed in triplicate, and the mean for the
crossing points of triplicates was used in subsequent cal-
culations. Data were normalized relative to 18S RNA
[76,77]. Levels of gene expression were expressed as
fold-change relative to denervated muscle from animals
that were administered vehicle and sacrificed at 7 days
using the 2
-ΔΔCt method [78]. Data are shown as mean
± SEM.
Western blotting
Gastrocnemius (20 mg) was homogenized in 200 μlo f
ice-cold lysis buffer (Cell Signaling) containing protease
and phosphatase inhibitors (Roche) using a Polytron.
Homogenates were cleared by centrifugation at 4°C in a
microcentrifuge. Proteins were denatured by boiling in
SDS-PAGE sample buffer containing b-mercaptoethanol
and resolved by SDS-PAGE. Proteins were then electro-
phoretically transferred to PVDF membranes and
probed with appropriate antibody. In these studies,
immunoreactive bands were visualized by chemilumine-
sence using ECL plus western-blotting detection system
(GE healthcare) and captured on photographic film with
subsequent digitization of images using a scanner. Inten-
sity of bands on digitized images was quantified using
Imagequant TL (GE Life Sciences, Piscataway, NJ).
Choice of a protein for normalization was challenging
for these studies because long-term denervation resulted
in profound alterations in levels of many cellular
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Page 14 of 17proteins, which was readily appreciated on Coomassie
Blue-stained SDS-page gels of skeletal muscle lysates.
Commonly used housekeeping genes such as b-tubulin,
a-actin and GAPDH proved to be unreliable for animals
with prolonged denervation. Therefore, we have used
the intensity of a neighboring non-specific band for nor-
malization. Antibodies that were used in these studies
include: RCAN2 (mouse polyclonal anti-DSCR1L1,
Novus Biologicals, Littleton, CO, 1:500 dilution),
FOXO1 (L27) (Cell signaling, Danvers, MA, 1:1,000
dilution), REDD2 (Abcam, Cambridge, MA, 1:500 dilu-
tion), Apo D (Abcam, 1:1,000 dilution), and anti-b-tubu-
lin (Abcam, 1:2,000 dilution). Data are shown as mean ±
SEM, and differences among means were determined by
ANOVA as above.
Statistics
For real time PCR and western blotting data, differ-
ences among means were determined using one way
ANOVA with a Newman-Keuls multiple comparison
test post-hoc to test for significance of differences
between pairs of means. Linear regression analysis was
used to test correlations. Calculations were performed
using Graphad Prism 4.0c (Graph Pad Software, San
Diego, CA).
Additional material
Additional file 1: Genes changed by nandrolone at 7 days (Pool A).
The file lists genes for which expression was altered by nandrolone at 7
days (Pool A), as well as a description of each gene, its gene symbol, the
name of probe set, and how much its expression changed.
Additional file 2: Genes with altered expression at 35 versus 7 days
after denervation (Pool E). The file lists genes for which expression was
different at 35 versus 7 days after denervation, as well as a description of
each gene, its gene symbol, the name of probe set, and how much its
expression changed.
Additional file 3: Genes altered by nandrolone at 35 days (Pool B).
The file lists genes for which expression was altered by nandrolone at 35
days as well as a description of each gene, its gene symbol, the name of
probe set, and how much its expression changed.
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